| Prev Close: | 263.64 |
|---|---|
| Open: | 264.26 |
| Bid: | 245.87 x 100 |
| Ask: | 261.58 x 100 |
| 1y Target Est: | 287.06 |
| Beta: | 0.84 |
| Next Earnings Date: | 22-Jul-13 |
| Day's Range: | 255.09 - 266.05 |
|---|---|
| 52wk Range: | 107.31 - 283.99 |
| Volume: | 804,876 |
| Avg Vol (3m): | 1,107,490 |
| Market Cap: | 25.18B |
| P/E (ttm): | 34.76 |
| EPS (ttm): | 7.48 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Regeneron and Sanofi: An Unstoppable Biotech Duo?at Motley Fool(Tue 6:32PM EDT)
- New Drug May Help Some Asthmatics, Study Findsat New York Times(Tue 4:12PM EDT)
- New Asthma Drug Generates Excitement For Patients -- And Its Makerat Forbes(Tue 8:52AM EDT)
- InPlay: Regeneron Pharms and Sanofi and announce publication of positive Phase 2a results of dupilumab in asthma in the New England Journal of MedicineBriefing.com(Tue 8:15AM EDT)
- Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of MedicinePR Newswire(Tue 8:15AM EDT)
- Regeneron, Sanofi asthma drug seen as potential game changerat Reuters(Tue 8:14AM EDT)
- Regeneron settles all pending litigation with Roche's Genentechat Reuters(Mon, May 20)
- Regeneron Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 10:00 AMat Seeking Alpha(Mon, May 20)
- 5 Stocks Underperforming Today In The Drugs Industryat TheStreet(Mon, May 20)
- REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Mon, May 20)
- Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN)at TheStreet(Mon, May 20)
- 2 Healthcare Companies And 1 Consumer Goods Company With Recent Intensive Insider Sellingat Seeking Alpha(Mon, May 20)
- Will ASCO Unlock Big Value in This Cancer Drug Class?at Motley Fool(Sat, May 18)
- IBD 50 Stocks Delivering Strong Earnings, Sales Gainsat Investor's Business Daily(Fri, May 17)
- Coverage initiated on Regeneron Pharms by UBSBriefing.com(Fri, May 17)
Press Releases
Reports
- REGN: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 21)
- Trading Report for (REGN). A detailed report, including free correlated market...Stock Traders Daily(May 21)
- The Investment Rate - a measure of investment demand.Stock Traders Daily(May 21)